

Big News from API!

API is leading the way to a bright future for life sciences with the Government of Canada's support of \$80.5 million for the **Canadian Critical Drug Initiative (CCDI)** – a revolutionary project that will create a research, commercialization and manufacturing hub in Edmonton. **CCDI addresses gaps that have limited success for the life sciences industry in Canada.**

Gap

- Lack of small molecule production
- Lack of manufacturing (fill/finish) facilities
- Ongoing drug shortages in Canada
- Support for research commercialization

Solution

- Build a new 40,000+ square foot manufacturing facility
- Upgrade the Biotechnology Business Development Centre (BBDC)
- Produce up to 4 drugs currently in short supply
- Develop therapeutics from the Li Ka Shing Applied Virology Institute

What will this accomplish?

- API will be able to support commercialization from early drug discovery, to clinical trials, to manufacturing
- More than 350 jobs in the Edmonton region
- Canadian ideas to be commercialized IP here, not abroad
- Attract more companies and investment

CCDI is a partnership between





api

APPLIED
PHARMACEUTICAL
INNOVATION

appliedpharma.ca

CCDI The Details

The CCDI project will add much-needed capacity to produce and manufacture small molecule drugs, help new drugs be developed, and boost the life sciences industry. Funding will be used to:

- Build and equip a new 40,000+ sq. ft. manufacturing facility that can produce small-molecule therapeutics from active pharmaceutical ingredients to finished product.
- Upgrade the 72,000 sq. ft. Biotechnology Business Development Centre (BBDC).
- Produce up to 4 critical hospital drugs that are high-risk due to market challenges, creating a secure supply of drugs critical to Canadian's health, and a facility that can be mobilized in the event of a crisis.
- Propel innovations from researchers at the La Ki Shing Applied Virology Institute and others across Canada that will provide life-saving drugs and preventatives, such as antivirals for Covid-19.
- Create more than 350 high quality jobs in the Edmonton region.
- Increase API's ability to support more companies through all phases of drug development, from early drug discovery to clinical trials to manufacturing.

New Manufacturing Facility

- Anticipated opening: 2026
- Key facilities and equipment available at the manufacturing facility:
 - > Sterile/aseptic fill/finish facility, capable of an annual throughput of up to 70M doses
 - > Multipurpose robotic filling line for small to medium volumes ranging from 1ml to 100ml; both liquid and powder fill; over 4,000 vials per hour
 - > Rotating autoclave for emulsion products
 - > 2 - 4 manufacturing suites
 - > Cold storage and flash freezer, with capacity to handle RNA vaccines

Upgrades to the BBDC

- Anticipated completion: 2024
- Upgrade the 72,000 square foot Biotechnology Business Development Centre to include:
 - > an additional Good Laboratory Practice (GLP) lab
 - > core facilities and improvements to enable the incubation of life science scale-up companies
 - > small molecule chemical synthesis capable of producing 200 litre batch sizes of small molecule active pharmaceutical ingredients